Novavax Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Novavax's earnings have been declining at an average annual rate of -16.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 33.6% per year.
Belangrijke informatie
-16.7%
Groei van de winst
-1.8%
Groei van de winst per aandeel
Biotechs Groei van de industrie | -14.6% |
Inkomstengroei | 33.6% |
Rendement op eigen vermogen | n/a |
Nettomarge | -29.8% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Novavax geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 988 | -294 | 446 | 0 |
31 Mar 24 | 997 | -399 | 427 | 0 |
31 Dec 23 | 984 | -545 | 457 | 0 |
30 Sep 23 | 1,050 | -549 | 464 | 0 |
30 Jun 23 | 1,597 | -587 | 479 | 0 |
31 Mar 23 | 1,359 | -1,155 | 505 | 0 |
31 Dec 22 | 1,982 | -658 | 489 | 0 |
30 Sep 22 | 1,847 | -1,322 | 411 | 0 |
30 Jun 22 | 1,291 | -1,476 | 366 | 0 |
31 Mar 22 | 1,403 | -1,318 | 331 | 0 |
31 Dec 21 | 1,146 | -1,744 | 298 | 0 |
30 Sep 21 | 1,204 | -1,075 | 273 | 0 |
30 Jun 21 | 1,182 | -950 | 252 | 0 |
31 Mar 21 | 919 | -615 | 196 | 0 |
31 Dec 20 | 476 | -418 | 143 | 0 |
30 Sep 20 | 205 | -273 | 92 | 0 |
30 Jun 20 | 50 | -93 | 43 | 0 |
31 Mar 20 | 18 | -115 | 35 | 0 |
31 Dec 19 | 19 | -133 | 34 | 0 |
30 Sep 19 | 16 | -150 | 35 | 0 |
30 Jun 19 | 21 | -177 | 36 | 0 |
31 Mar 19 | 29 | -182 | 34 | 0 |
31 Dec 18 | 34 | -185 | 34 | 0 |
30 Sep 18 | 39 | -186 | 34 | 0 |
30 Jun 18 | 39 | -186 | 34 | 0 |
31 Mar 18 | 35 | -186 | 34 | 0 |
31 Dec 17 | 31 | -184 | 34 | 0 |
30 Sep 17 | 26 | -190 | 34 | 0 |
30 Jun 17 | 21 | -212 | 40 | 0 |
31 Mar 17 | 17 | -247 | 45 | 0 |
31 Dec 16 | 15 | -280 | 47 | 0 |
30 Sep 16 | 16 | -302 | 47 | 0 |
30 Jun 16 | 19 | -269 | 43 | 0 |
31 Mar 16 | 31 | -210 | 36 | 0 |
31 Dec 15 | 36 | -157 | 31 | 0 |
30 Sep 15 | 37 | -110 | 27 | 0 |
30 Jun 15 | 39 | -96 | 23 | 0 |
31 Mar 15 | 33 | -94 | 21 | 0 |
31 Dec 14 | 31 | -83 | 20 | 0 |
30 Sep 14 | 33 | -65 | 18 | 0 |
30 Jun 14 | 29 | -61 | 17 | 0 |
31 Mar 14 | 25 | -56 | 15 | 0 |
31 Dec 13 | 21 | -52 | 15 | 0 |
Kwaliteitswinsten: NVV1 is currently unprofitable.
Groeiende winstmarge: NVV1 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: NVV1 is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Versnelling van de groei: Unable to compare NVV1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: NVV1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: NVV1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.